BIO-RAD LABORATORIES, INC. acquires Stilla Technologies

BIO-RAD LABORATORIES, INC. acquired Stilla Technologies for approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M), a transaction completed in June 2025, structured as all cash plus contingent consideration.

Stilla Technologies operates in Life Science, is based in France. Stilla Technologies is a commercial-stage life science company that develops and markets next-generation droplet digital PCR (Polymerase Chain Reaction) systems supporting a broad range of genetic and molecular testing applications.

The strategic rationale for the transaction was to strengthen our offering in droplet digital PCR and facilitate entry into new molecular testing markets.

Commercial-stage, next-generation droplet digital PCR technology adjacent to Bio-Rad's existing ddPCR franchise. Strengthens Bio-Rad's droplet digital PCR offering and supports entry into new molecular testing markets. Life Science segment

Stilla is a commercial-stage life science company that develops and markets next-generation droplet digital Polymerase Chain Reaction (PCR) systems, which supports a broad range of genetic and molecular testing applications.Bio-Rad Laboratories FY2025 10-K, Acquisitions note

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.